Search Results | Blood | American Society of Hematology

1-20 of 505

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Clinical Trials & Observations

Ranjana Advani, Alison J Moskowitz, Nancy L. Bartlett, Julie Vose, Radhakrishnan Ramchandren, Tatyana Feldman, Ann S. LaCasce, Beth Christian, Stephen M. Ansell, Craig H. Moskowitz, Lisa Brown, Chiyu Zhang, David Taft, Sahar Ansari, Mariana Sacchi, Linda Ho, Alex F. Herrera

Blood blood.2020009178.

DOI: https://doi.org/10.1182/blood.2020009178

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes of rare patients with a primary cutaneous CD30 + lymphoproliferative disorder developing extracutaneous disease

Clinical Trials & Observations

Rutger C. Melchers, Rein Willemze, Joost S. P. Vermaat, Patty M. Jansen, Laurien A. Daniëls, Hein Putter, Marcel W. Bekkenk, Ellen R. M. de Haas, Barbara Horvath, Michelle M. van Rossum, Cornelus J. G. Sanders, Joep C. J. M. Veraart, Maarten H. Vermeer, Koen D. Quint

Blood (2020) 135 (10): 769–773.

DOI: https://doi.org/10.1182/blood.2019002799

Published: 2020

Includes: Supplemental data

Journal Articles

Brentuximab vedotin in the treatment of CD30 + PTCL

Clinical Trials & Observations

Stefan K. Barta, Jerald Z. Gong, Pierluigi Porcu

Blood (2019) 134 (26): 2339–2345.

DOI: https://doi.org/10.1182/blood.2019001821

Published: 2019

Journal Articles

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Jaclyn Basso, RN, MSN, PNP, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Aliza Gardenswartz, MD, Qiuhu Shi, PhD, Perry Gerard, MD MBA, FACR, Humayan Islam, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 127.

DOI: https://doi.org/10.1182/blood-2019-128684

Published: 2019

Journal Articles

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Blood (2019) 134 (Supplement_1): 130.

DOI: https://doi.org/10.1182/blood-2019-126787

Published: 2019

Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 464.

DOI: https://doi.org/10.1182/blood-2019-122781

Published: 2019

Journal Articles

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

Giuseppe Lia, PhD, Clara Di Vito, PhD, Marta Tapparo, PhD, Stefania Bruno, Elisa Zaghi, Michela Calvi, Lucia Brunello, Jacopo Mariotti, MD, Lorenzo Comba, Luisa Giaccone, Martina Fascì, Mario Boccadoro, Andrea Evangelista, MSc, Luca Castagna, MD, Giovanni Camussi, Domenico Mavilio, Benedetto Bruno, MD

Blood (2019) 134 (Supplement_1): 598.

DOI: https://doi.org/10.1182/blood-2019-126521

Published: 2019

Journal Articles

Proteomic Profiling of HTLV-1 Carriers and ATL Patients Reveal TNFR2 As a Novel Diagnostic and Chemosensitivity Biomarker for ATL

Carmina Louise Hugo Guerrero, MS, Yoshiko Yamashita, PhD, Megumi Kuba-Miyara, PhD, Naoki Imaizumi, PhD, Shugo Sakihama, PhD, Masaki Hayashi, MD, Takashi Miyagi, MD PhD, Satoko Morishima, MD PhD, Kennosuke Karube, MD PhD, Yuetsu Tanaka, PhD, Hiroaki Masuzaki, MD PhD, Takuya Fukushima, MD PhD

Blood (2019) 134 (Supplement_1): 660.

DOI: https://doi.org/10.1182/blood-2019-129817

Published: 2019

Journal Articles

Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort

Jennifer Agrusa, MD, Elmoataz A Abdel Fattah, MBBCh, Howard Lin, BS, Rikhia Chakraborty, PhD, Brooks Scull, MS, Harshal Abhyankar, MS, Nmazuo Wudo Ozuah, MBBS, Olive S. Eckstein, MD, Terzah M Horton, MD PhD, Kala Kamdar, MD, Kenneth L. McClain, MD PhD, Chris Tsz-Kwong Man, PhD, Carl E. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 2773.

DOI: https://doi.org/10.1182/blood-2019-125982

Published: 2019

Journal Articles

Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term

Paola Ghione, MD, Peter Cordeiro, MD, Venkatraman Seshan, PhD, Natasha Galasso, Nivetha Ganesan, MPH, Qunying Hu, Ahmet Dogan, MD PhD, Steven M. Horwitz, MD

Blood (2019) 134 (Supplement_1): 2842.

DOI: https://doi.org/10.1182/blood-2019-122572

Published: 2019

Journal Articles

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Philipp Bernhard Staber, MD PhD, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, MD, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, PhD, Marius E Mayerhoefer, Richard Greil, MD, Ingrid Simonitsch-Klupp, MD, Lukas Kenner, MD, Ulrich Jaeger, MD

Blood (2019) 134 (Supplement_1): 4037.

DOI: https://doi.org/10.1182/blood-2019-129955

Published: 2019

Journal Articles

Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016

Cesar Gentille Sanchez, MD, Joe Ensor, PhD, Akshjot Puri, MD, Jasleen K. Randhawa, MD, Shilpan S. Shah, MD, Sai Ravi Kiran Pingali, MD

Blood (2019) 134 (Supplement_1): 4022.

DOI: https://doi.org/10.1182/blood-2019-131991

Published: 2019

Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD

Blood (2019) 134 (Supplement_1): 4023.

DOI: https://doi.org/10.1182/blood-2019-123166

Published: 2019

Journal Articles

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

Wenyu Shi, Jian-Yong Li, MD PhD

Blood (2019) 134 (Supplement_1): 4069.

DOI: https://doi.org/10.1182/blood-2019-130063

Published: 2019

Journal Articles

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Sairah Ahmed, MD, Julie Lisano, PharmD, Trevor Newhook, MS

Blood (2019) 134 (Supplement_1): 4054.

DOI: https://doi.org/10.1182/blood-2019-121523

Published: 2019

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

DOI: https://doi.org/10.1182/blood-2019-129632

Published: 2019

Journal Articles

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

Blood (2019) 134 (Supplement_1): 4028.

DOI: https://doi.org/10.1182/blood-2019-130223

Published: 2019

Journal Articles

Novel Immunotherapeutic Approaches for Hodgkin Lymphoma

Barbara Savoldo, MD PhD, Natalie S Grover, MD, Carlos A. Ramos, MD, Gianpietro Dotti, MD

Blood (2019) 134 (Supplement_1): SCI-9.

DOI: https://doi.org/10.1182/blood-2019-121075

Published: 2019

Journal Articles

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

William Pearse, MD, Barbara Pro, MD, Leo I. Gordon, MD, Reem Karmali, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Amir Behdad, MD, Andreas Klein, MD, Adam M. Petrich, MD, Borko Jovanovic, PhD, Sonali M. Smith, MD, Andrew G Evans, MD PhD

Blood (2019) 134 (Supplement_1): 351.

DOI: https://doi.org/10.1182/blood-2019-127390

Published: 2019

Journal Articles

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Alison J. Moskowitz, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Julie M Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MMSc, Beth A. Christian, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, Lisa Brown, David Taft, Sahar Ansari, Daniel E. Zak, PhD, Mariana Sacchi, MD, Thomas Manley, MD, Alex F. Herrera, MD

Blood (2019) 134 (Supplement_1): 238.

DOI: https://doi.org/10.1182/blood-2019-122576

Published: 2019

2 3 4 5

NARROW

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Outcomes of rare patients with a primary cutaneous CD30 + lymphoproliferative disorder developing extracutaneous disease

Brentuximab vedotin in the treatment of CD30 + PTCL

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

Proteomic Profiling of HTLV-1 Carriers and ATL Patients Reveal TNFR2 As a Novel Diagnostic and Chemosensitivity Biomarker for ATL

Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort

Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

Novel Immunotherapeutic Approaches for Hodgkin Lymphoma

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only